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 Currently, AKI diagnosis depends on 
detection of a relative serum creatinine 
(SCr) increase from baseline or an abso-
lute SCr value above a certain threshold. 1 
Substantial research over the past decade 
has been focused on discovery and valida-
tion of urinary biomarkers to detect acute 
kidney injury (AKI) development prior to 
a rise in SCr. 2 Th e impetus for this research 
was the recognition that even small 
increases in SCr (for example,   0.3  mg / dl) 
in hospitalized patients are associated with 
increased morbidity and mortality, sug-
gesting that small elevations in SCr may 
refl ect signifi cant kidney damage and be 
associated with poor patient outcomes, 
thus rendering SCr a late marker of AKI. 3 
AKI researchers refer to the AKI biomar-
ker quest as the  “ search for the renal tro-
ponin I, ” implying that such putative 
earlier AKI biomarker use could allow ear-
lier detection and potential intervention. 4 
 Standard reporting practice for uri-
nary biomarker assessment includes both 
raw concentrations and values normal-
ized to urinary creatinine. For many 
years, it has been standard practice for 
clinicians to normalize urinary excretion 
of many diff erent biomarkers to urine 
creatinine in chronic conditions such as 
microalbuminuria in diabetes mellitus 
and proteinuria in nephrotic syndromes. 
Th e rationale for urine creatinine nor-
malization is clear in these disease states, 
as urinary excretion of any biomarker 
that is fi ltered via the glomerulus will be 
aff ected by the glomerular fi ltration rate 
and resultant urinary fl ow. Lack of nor-
malization may lead to falsely low 
biomarker concentration interpretation 
in chronic states of reduced glomerular 
fi ltration rate. In fact, spot assessments 
of biomarkers of chronic kidney diseases 
normalized to urine creatinine concen-
trations have supplanted timed collec-
tions in many instances, including 
assessments of microalbuminuria, pro-
teinuria, and calciuria. However, 
although it has been assumed that nor-
malization of spot urinary biomarkers to 
urine creatinine in an acute disease, such 
as AKI, can achieve the same goal, 
Waikar  et al. 5 (this issue) now challenge 
that assumption ( Figure 1 ). 
 Th e hypothesis of Waikar  et al. , 5 and 
their cause for concern, emanate from the 
basic principle that urinary biomarker 
excretion and creatinine excretion may be 
aff ected diff erently in acute disease states 
(whereas they should be aff ected more 
similarly in chronic disease states). Th is 
concept certainly has face validity, as cre-
atinine excretion in AKI is, by defi nition, 
a dynamic process, governed by both 
glomerular fi ltration and tubular secre-
tion, while diff erent urinary AKI biomar-
kers reflect different functional and 
structural sequelae of damage. The 
authors suggest that normalization of uri-
nary AKI biomarkers to urine creatinine 
may overestimate acute kidney damage as 
a result of acute and unstable changes in 
creatinine clearance (CrCl) ( Figure 1 ). 
Th ey provide a number of simulations 
demonstrating the effect of different 
reductions in CrCl in the acute phase of 
AKI, as well as the eff ect of increases in 
CrCl on AKI biomarker assessment in the 
recovery phase. Th e authors then go on to 
test their hypothesis in a small sample of 
adults with kidney transplants or critical 
illness and indeed show that urinary 
biomarker excretion and creatinine excre-
tion are not linked and vary substantially 
in the acute setting. Their pilot study 
examines the benefi t of timed urine col-
lections of creatinine and kidney injury 
molecule-1 (KIM-1) to more accurately 
ascertain resolution of kidney damage 
aft er renal transplantation. To their credit, 
the authors acknowledge the practical 
barriers to obtaining timed urine collec-
tions and do not go so far as to recom-
mend abandonment of spot biomarker 
assessments normalized to urine creati-
nine. Rather, they suggest repeated 
biomarker assessment and determina-
tions of thresholds to identify AKI. 
 Waikar  et al. 5 used a number of assump-
tions, however, in their simulations. Th e 
most troublesome, which is not addressed 
in their Discussion, is the requirement 
of a constant urinary biomarker excretion 
rate. Such an assumption may not be 
justifi ed, as one could reasonably expect 
changing concentrations throughout the 
course of AKI depending on the tubular 
site and intensity of injury. In fact, serum 
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troponin I concentrations are interpreted 
in that manner to assess both the time 
course and the intensity of myocardial 
ischemia. In addition, the scenario of kid-
ney transplantation encompasses a situa-
tion of known kidney damage and recovery 
but not early detection, which was the 
focus of their fi rst two simulations. While 
kidney transplantation provides an excel-
lent venue to study biomarkers in this con-
text, timed urine collections are easy to 
perform in this setting, and SCr is probably 
a reasonable clinical marker to assess for 
recovery of kidney function aft er kidney 
transplantation. 
 In contrast, the current primary chal-
lenge in improving AKI outcomes, as 
noted above, has been in the late detection 
of AKI in hospitalized patients. Multiple 
studies have demonstrated that certain 
urinary biomarkers appear in elevated 
concentrations before SCr rises and can 
predict the ultimate severity of AKI. 6 – 9 In 
these instances, it is likely that both the 
urinary biomarker and creatinine concen-
trations are in great flux, but it is the 
requirement of biomarker concentration 
increase in relation to decrease in CrCl 
that can amplify the utility of the biomar-
ker for detection of AKI. One should 
expect the rise in biomarker to precede 
the decrease in CrCl, if that biomarker is 
going to serve well as an early marker of 
AKI. If all that were needed were a 
decrease in CrCl to detect AKI early, then 
we could dispense with assessment of AKI 
biomarkers altogether and just perform 
spot assessments of urinary creatinine. 
 Nevertheless, Waikar  et al. 5 have made 
a clear case for avoiding reliance on a 
single biomarker result obtained at one 
point in time in a dynamic illness such 
as AKI. In addition, their simulations 
represent hypotheses that should be 
easily tested as discovery and validation 
of new biomarkers proceed in the com-
ing years. As a result of their study, 
future clinical and translational studies 
to  evaluate urinary biomarkers to pre-
dict AKI development, severity, and 
recovery would be strengthened by 
assessment of a timed urine creatinine 
collection for comparison. 
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 Figure 1  |  Spot urinary biomarker / creatinine ratios in acute kidney injury are unreliable. The interpretation of an increased ratio of biomarker to 
creatinine depends on knowledge of the change in excretion of the biomarker relative to the change in creatinine excretion. As creatinine excretion is 
unstable in acute kidney injury (AKI), changes in the ratio cannot be determined unless the directional change of each is known. 
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 Transplantation is regarded as the therapy 
of choice for end-stage organ failure; how-
ever, the prolonged acceptance of trans-
planted organs requires long-term use of 
immunosuppressive drugs. Th is treatment 
risks infection and a range of side eff ects, 
which, along with the inexorable chronic 
allograft  injury, limit the life of the graft s 
and the patients. 1 The most appealing 
solution to these problems is the induction 
of transplantation tolerance, defi ned as 
 “ the absence of acute and chronic rejection 
and indefi nite graft  survival with normal 
function in an immunocompetent host. ” 2 
Such a condition has been successfully 
induced in rodent models of solid-organ 
transplantation by several therapeutic 
strategies that, however, turned out to be 
diffi  cult to apply in the clinical setting 
because of intrinsic toxicity. 1 
 Nevertheless, patients with liver and, 
more rarely, kidney grafts that were 
functioning for many years aft er cessa-
tion of immunosuppression have been 
reported. Most of these cases are the 
result of noncompliance or withdrawal 
mandated by drug-associated complica-
tions. 1 Demonstrating  ‘ true ’ tolerance is 
not possible in these patients. Biopsies 
are oft en unavailable to exclude subclin-
ical rejection, and some of these patients 
eventually developed chronic rejection 
or deterioration of graft  function from 
nonimmune causes. In addition, donor-
specifi c immunocompetence, which in 
experimental animals is documented by 
the ability to accept a second graft  of the 
same donor origin while being able to 
reject a third-party graft , cannot be dem-
onstrated  in vivo in humans. Th us the 
less stringent clinical defi nition of oper-
ational tolerance or drug-free long-term 
graft  function has been adopted. 
 Studies on drug-free patients with trans-
plants are very fascinating, as they inspire 
us by clearly demonstrating that tolerance 
is a biological possibility in humans, at 
least transiently. In addition, understand-
ing the mechanisms underlying spontane-
ous operational tolerance is of great 
importance, as it may help us to fi nd spe-
cifi c markers to guide progressive immu-
nosuppressive drug minimization in 
selected patients, as well as to develop and 
monitor new tolerance induction proto-
cols in humans. 
 Several studies in recent years have largely 
investigated the phenotype of peripheral 
blood immune cells in operationally toler-
ant patients with the goal of disclosing the 
immunological signature behind opera-
tional tolerance, with disparate and oft en 
confl icting results. 3 – 8 A moot point in such 
studies is the choice of adequate compara-
tors, as the ideal control to operationally 
tolerant patients, that is, non-immunosup-
pressed patients rejecting the graft , is obvi-
ously hard to achieve. Th us, operationally 
tolerant patients have been compared with 
those with chronic rejection, who have a 
transplant but are under immunosuppres-
sion and likely display an infl ammatory 
response; or with patients with stable graft  
function under immunosuppression, who 
share graft  function stability with opera-
tionally tolerant patients but are immuno-
suppressed; or with healthy individuals, 
who share with operationally tolerant 
patients the absence of immunosuppression 
but have not received a graft . 
 In a study in 16 operationally tolerant 
European liver transplant recipients, 3 
microarray profi ling in peripheral blood 
mononuclear cells identified a gene 
expression signature that could discrim-
inate tolerant from immunosuppression-
dependent recipients. Genes expressed 
by    T cells and coding for natural killer 
receptors were upregulated in peripheral 
blood of tolerant patients. In addition, 
as compared with either non-tolerant 
immunosuppressed patients or healthy 
individuals, tolerant patients exhibited 
greater numbers of CD4   +   CD25   +  
regulatory T cells and an expansion of 
the V  1   +   subset of    T cells, which 
resulted in a reversal of the normal 
V  1 / V  2 ratio. Th e same increases of 
CD4   +   CD25 high regulatory T cells and of 
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